ClpP agonists inhibited tumor-initiating ability in vitro and in vivo. Mechanistically, ClpP agonists dysregulated multiple signaling pathways involved with CSC functions, including the mevalonate, YAP, Myc, and HIF pathways. This evidence concerns the gene CLPP and neoplasm.